Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

20.44 -0.76 (-3.58%)
Streaming Delayed Price Updated: 10:48 AM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Upgrades 
Via Benzinga
Recap: ADMA Biologics Q2 Earnings
  ADMA Biologics (NASDAQ:ADMA) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
7 A-Rated Stocks to Buy for Less Than $10
While stocks under $10 don't carry the cache of blue-chip stocks, the returns that they offer can be enticing. 
Via InvestorPlace
7 Top-Rated Biotech Stocks to Buy for Q4
A new White House program makes these seven names some outstanding biotech stocks to buy for the fourth quarter. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Stocks That Made New Highs On Friday, Aug. 19
On Friday, in spite of the stock market being down, there were several stocks that actually made new highs. 
Via Talk Markets
ADMA Biologics: Earnings Outlook
  ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. Analysts estimate that ADMA... 
Via Benzinga
Why ADMA Biologics Shares Are Rising Today
ADMA Biologics Inc (NASDAQ: ADMA) shares are trading higher Monday after the company announced it received U.S. Food and Drug Administration approval for its sixth plasma collection center. 
Via Benzinga
Looking Into ADMA Biologics's Return On Capital Employed
Benzinga Pro data, ADMA Biologics (NASDAQ:ADMA) reported Q1 sales of $29.10 million. Earnings fell to a loss of $25.01 million, resulting in a 50.2% decrease from last quarter. 
Via Benzinga
Recap: ADMA Biologics Q1 Earnings
ADMA Biologics (NASDAQ:ADMA) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings ADMA Biologics missed estimated... 
Via Benzinga
Earnings Outlook For ADMA Biologics
ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that ADMA... 
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:... 
Via Benzinga
ADMA Biologics's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q4, ADMA Biologics's (NASDAQ:ADMA) reported sales totaled $26.38 million. Despite a 6.0% increase in earnings, the company posted a... 
Via Benzinga
ADMA Biologics' Q4 Top-Line Surpass Estimates, Concludes $175M Debt Refinancing
ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue... 
Via Benzinga
Earnings Scheduled For March 24, 2022
Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • Pioneer Muni High Inc (NYSE:MAV) is expected to... 
Via Benzinga
ADMA Biologics's Earnings Outlook
ADMA Biologics (NASDAQ:ADMA) is set to give its latest quarterly earnings report on Thursday, 2022-03-24. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative... 
Via Benzinga
ADMA Biologics Shares Gain As Interim Q4 Sales Beat Expectation
ADMA Biologics Inc (NASDAQ: ADMA) expects Q4 Sales of approximately $26 million, compared to $14 million a year ago and better than the consensus of $21.76 million.... 
Via Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ATI Physical Therapy (NYSE:ATIP) stock increased by 22.7% to $3.73 during Friday's regular session. Trading volume for ATI Physical Therapy's stock is 14.3... 
Via Benzinga
91 Biggest Movers From Yesterday
Gainers NuZee, Inc. (NASDAQ: NUZE) shares jumped 164.5% to settle at $5.29 on Thursday. NuZee manufacturing partner, Cuvee Coffee, reported an expansion into select Walmart... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liquidia (NASDAQ:LQDA) stock inc... 
Via Benzinga
54 Stocks Moving In Thursday's Mid-Day Session
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares gained 42.6% to $9.68. Pioneer Power Solutions recently announced the launch of its E-Boost portfolio of mobile... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 11, 2021
Upgrades Barrington Research upgraded the previous rating for Clear Channel Outdoor Holdings Inc (NYSE: 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers ADMA Biologics (NASDAQ:ADMA) shares moved upwards by 11.42% to $1.56 during Thursday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
ADMA Biologics Shares Rise On Lower Than Expected Q3 Loss, Sales Double
ADMA Biologics Inc (NASDAQ: ADMA) achieved Q3 sales of $20.7 million, + 101% Y/Y, beating the consensus of $18.72 million. The increase was favorably impacted by the... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're ready to start off another busy day of trading with a breakdown of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
28 Stocks Moving in Thursday's Pre-Market Session
Gainers Fossil Group, Inc. (NASDAQ: FOSL) rose 33.8% to $18.52 in pre-market trading after the company reported better-than-expected Q3 sales results and raised FY21 net sales... 
Via Benzinga
ADMA Biologics Inc (ADMA) Q3 2021 Earnings Call Transcript
ADMA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To Pursue Other Opportunities MorphoSys AG (NASDAQ:... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.